Eleonora Di Paolo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Eleonora Di Paolo has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Elena Cattaneo
Department of Biosciences, University of Milan, Milan, Italy
4 shared publications - Marta Valenza
Department of Biosciences, University of Milan, Milan, Italy
4 shared publications - Claudio Caccia
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
2 shared publications Costanza Ferrari Bardile
Department of BioSciences and Centre for Stem Cell Research, Università degli Studi di Milano, 20122 Milan, Italy
2 shared publications- Daniela Belletti
Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
2 shared publications - Giovanni Tosi
University of Modena and Reggio Emilia
2 shared publications
Latest Publications
- 1 February 2017
- Published by Elsevier in Neurobiology of Disease
- Vol. 98, 66-76
Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington's disease: A cross-validation study in Q175 knock-in mice
- 1 February 2017
- Published by Elsevier in Neurobiology of Disease
- Vol. 98, 66-76
Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington's disease: A cross-validation study in Q175 knock-in mice
- 13 September 2016
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (Suppl 1) , A95.2-A95
L16 Identifying a therapeutic regimen for cholesterol delivery to huntington’s disease brain
Background Several studies provide evidence that brain cholesterol biosynthesis is reduced in several rodent models of Huntington’s disease1,2,3 and a similar reduction is also measurable in HD patients, even before disease onset.4,5 This dysfunction may be detrimental for neuronal cells, especially given that locally synthesised cholesterol is implicated in neurite outgrowth, synapses formation and maintenance, synaptic activity and integrity, and optimal neurotransmitter release.6 Aims We tested the hypothesis that exogenous cholesterol supplementation in the brain of HD mice, by applying different delivery strategies, could rescue aspects of neuronal dysfunction. Methods and results In our first study, the delivery of cholesterol via brain-permeable polymeric nanoparticles (g7-NPs-Chol) rescued synaptic communication, protected from cognitive decline and partially improved global activity in HD mice (Valenza et al., 2015). In a second ongoing study, cognitive functions are significantly improved in HD mice intrastriatally infused with cholesterol, at a continuous rate, via osmotic minipumps, compared to vehicle-treated and untreated HD mice. More recently, we have also adopted a third innovative strategy based on intranasal delivery of cholesterol and the relative preliminary results will be presented. Conclusions Our results highlight the positive effect of cholesterol supplementation to reverse the cascade of synaptic and neuronal alterations associated with the disease. To establish the therapeutic regimen for cholesterol administration will advance significantly towards the concept of cholesterol as a candidate drug in HD. References Valenza et al. J Neurosci 2005 Oct 26;25(43):9,932–7 Valenza et al. Hum Mol Genet 2007 Sep 15;16(18):2,187–98 Valenza et al. J Neurosci 2010 Aug 11;30(32):10,844–50 Leoni et al. Brain 2008 Nov;131(Pt 11):2,851–9 Leoni et al. Neurobiol Dis 2013 Jul;55:37–43 Pfrieger et al. Biochim Biophys Acta 2003 Mar 10;1610(2):271–80
- 13 September 2016
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (Suppl 1) , A95.2-A95
L16 Identifying a therapeutic regimen for cholesterol delivery to huntington’s disease brain
Background Several studies provide evidence that brain cholesterol biosynthesis is reduced in several rodent models of Huntington’s disease1,2,3 and a similar reduction is also measurable in HD patients, even before disease onset.4,5 This dysfunction may be detrimental for neuronal cells, especially given that locally synthesised cholesterol is implicated in neurite outgrowth, synapses formation and maintenance, synaptic activity and integrity, and optimal neurotransmitter release.6 Aims We tested the hypothesis that exogenous cholesterol supplementation in the brain of HD mice, by applying different delivery strategies, could rescue aspects of neuronal dysfunction. Methods and results In our first study, the delivery of cholesterol via brain-permeable polymeric nanoparticles (g7-NPs-Chol) rescued synaptic communication, protected from cognitive decline and partially improved global activity in HD mice (Valenza et al., 2015). In a second ongoing study, cognitive functions are significantly improved in HD mice intrastriatally infused with cholesterol, at a continuous rate, via osmotic minipumps, compared to vehicle-treated and untreated HD mice. More recently, we have also adopted a third innovative strategy based on intranasal delivery of cholesterol and the relative preliminary results will be presented. Conclusions Our results highlight the positive effect of cholesterol supplementation to reverse the cascade of synaptic and neuronal alterations associated with the disease. To establish the therapeutic regimen for cholesterol administration will advance significantly towards the concept of cholesterol as a candidate drug in HD. References Valenza et al. J Neurosci 2005 Oct 26;25(43):9,932–7 Valenza et al. Hum Mol Genet 2007 Sep 15;16(18):2,187–98 Valenza et al. J Neurosci 2010 Aug 11;30(32):10,844–50 Leoni et al. Brain 2008 Nov;131(Pt 11):2,851–9 Leoni et al. Neurobiol Dis 2013 Jul;55:37–43 Pfrieger et al. Biochim Biophys Acta 2003 Mar 10;1610(2):271–80
- Open Access
- 20 November 2015
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 7 (12) , 1547-1564
Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice
Brain cholesterol biosynthesis and cholesterol levels are reduced in mouse models of Huntington9s disease (HD), suggesting that locally synthesized, newly formed cholesterol is less available to neurons. This may be detrimental for neuronal function, especially given that locally synthesized cholesterol is implicated in synapse integrity and remodeling. Here, we used biodegradable and biocompatible polymeric nanoparticles (NPs) modified with glycopeptides (g7) and loaded with cholesterol (g7‐NPs‐Chol), which per se is not blood–brain barrier (BBB) permeable, to obtain high‐rate cholesterol delivery into the brain after intraperitoneal injection in HD mice. We report that g7‐NPs, in contrast to unmodified NPs, efficiently crossed the BBB and localized in glial and neuronal cells in different brain regions. We also found that repeated systemic delivery of g7‐NPs‐Chol rescued synaptic and cognitive dysfunction and partially improved global activity in HD mice. These results demonstrate that cholesterol supplementation to the HD brain reverses functional alterations associated with HD and highlight the potential of this new drug‐administration route to the diseased brain. Synopsis Cholesterol in brain is largely derived by local synthesis. One affected pathway in Huntington9s disease (HD) implicates that reduced production and/or availability of brain cholesterol may be detrimental for neuronal function. Polymeric nanoparticles (NPs) loaded with cholesterol, modified with glycopeptides g7 (g7‐NPs‐Chol) to cross the BBB after systemic injection, have been used to deliver cholesterol to the brain of HD mice. These NPs, applied for the first time to a brain disorder, are made of PLGA, which is approved by FDA in various drug delivery systems in humans. Systemic administration of g7‐NPs‐Chol (i) rescued synaptic communication in striatal medium‐sized spiny neurons, (ii) prevented cognitive decline, and (iii) restored the levels of proteins that compose the synaptic machinery in HD mice. g7‐NPs or cholesterol itself did not induce inflammatory response in the periphery, where almost all g7‐NPs are localized.
- 20 November 2015
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 7 (12) , 1547-1564
Open AccessCholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice
Brain cholesterol biosynthesis and cholesterol levels are reduced in mouse models of Huntington9s disease (HD), suggesting that locally synthesized, newly formed cholesterol is less available to neurons. This may be detrimental for neuronal function, especially given that locally synthesized cholesterol is implicated in synapse integrity and remodeling. Here, we used biodegradable and biocompatible polymeric nanoparticles (NPs) modified with glycopeptides (g7) and loaded with cholesterol (g7‐NPs‐Chol), which per se is not blood–brain barrier (BBB) permeable, to obtain high‐rate cholesterol delivery into the brain after intraperitoneal injection in HD mice. We report that g7‐NPs, in contrast to unmodified NPs, efficiently crossed the BBB and localized in glial and neuronal cells in different brain regions. We also found that repeated systemic delivery of g7‐NPs‐Chol rescued synaptic and cognitive dysfunction and partially improved global activity in HD mice. These results demonstrate that cholesterol supplementation to the HD brain reverses functional alterations associated with HD and highlight the potential of this new drug‐administration route to the diseased brain. Synopsis Cholesterol in brain is largely derived by local synthesis. One affected pathway in Huntington9s disease (HD) implicates that reduced production and/or availability of brain cholesterol may be detrimental for neuronal function. Polymeric nanoparticles (NPs) loaded with cholesterol, modified with glycopeptides g7 (g7‐NPs‐Chol) to cross the BBB after systemic injection, have been used to deliver cholesterol to the brain of HD mice. These NPs, applied for the first time to a brain disorder, are made of PLGA, which is approved by FDA in various drug delivery systems in humans. Systemic administration of g7‐NPs‐Chol (i) rescued synaptic communication in striatal medium‐sized spiny neurons, (ii) prevented cognitive decline, and (iii) restored the levels of proteins that compose the synaptic machinery in HD mice. g7‐NPs or cholesterol itself did not induce inflammatory response in the periphery, where almost all g7‐NPs are localized.
- Open Access
- 21 January 2015
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 8, 472
Fractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation
Neuronal death induced by overactivation of N-methyl-d-aspartate receptors (NMDARs) is implicated in the pathophysiology of many neurodegenerative diseases such as stroke, epilepsy and traumatic brain injury. This toxic effect is mainly mediated by NR2B-containing extrasynaptic NMDARs, while NR2A-containing synaptic NMDARs contribute to cell survival, suggesting the possibility of therapeutic approaches targeting specific receptor subunits. We report that fractalkine/CX3CL1 protects hippocampal neurons from NMDA-induced cell death with a mechanism requiring the adenosine receptors type 2A (A2AR). This is different from CX3CL1-induced protection from glutamate-induced cell death, that fully depends on A1R and requires in part A3R. We show that CX3CL1 neuroprotection against NMDA excitotoxicity involves D-serine, a co-agonist of NR2A/NMDAR, resulting in cyclic AMP-dependent transcription factor (CREB) phosphorylation.
- 21 January 2015
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 8, 472
Open AccessFractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation
Neuronal death induced by overactivation of N-methyl-d-aspartate receptors (NMDARs) is implicated in the pathophysiology of many neurodegenerative diseases such as stroke, epilepsy and traumatic brain injury. This toxic effect is mainly mediated by NR2B-containing extrasynaptic NMDARs, while NR2A-containing synaptic NMDARs contribute to cell survival, suggesting the possibility of therapeutic approaches targeting specific receptor subunits. We report that fractalkine/CX3CL1 protects hippocampal neurons from NMDA-induced cell death with a mechanism requiring the adenosine receptors type 2A (A2AR). This is different from CX3CL1-induced protection from glutamate-induced cell death, that fully depends on A1R and requires in part A3R. We show that CX3CL1 neuroprotection against NMDA excitotoxicity involves D-serine, a co-agonist of NR2A/NMDAR, resulting in cyclic AMP-dependent transcription factor (CREB) phosphorylation.
- 10 October 2014
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 22 (4) , 690-702
Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington’s disease
In the adult brain, neurons require local cholesterol production, which is supplied by astrocytes through apoE-containing lipoproteins. In Huntington's disease (HD), such cholesterol biosynthesis in the brain is severely reduced. Here we show that this defect, occurring in astrocytes, is detrimental for HD neurons. Astrocytes bearing the huntingtin protein containing increasing CAG repeats secreted less apoE-lipoprotein-bound cholesterol in the medium. Conditioned media from HD astrocytes and lipoprotein-depleted conditioned media from wild-type (wt) astrocytes were equally detrimental in a neurite outgrowth assay and did not support synaptic activity in HD neurons, compared with conditions of cholesterol supplementation or conditioned media from wt astrocytes. Molecular perturbation of cholesterol biosynthesis and efflux in astrocytes caused similarly altered astrocyte-neuron cross talk, whereas enhancement of glial SREBP2 and ABCA1 function reversed the aspects of neuronal dysfunction in HD. These findings indicate that astrocyte-mediated cholesterol homeostasis could be a potential therapeutic target to ameliorate neuronal dysfunction in HD.
- 10 October 2014
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 22 (4) , 690-702
Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington’s disease
In the adult brain, neurons require local cholesterol production, which is supplied by astrocytes through apoE-containing lipoproteins. In Huntington's disease (HD), such cholesterol biosynthesis in the brain is severely reduced. Here we show that this defect, occurring in astrocytes, is detrimental for HD neurons. Astrocytes bearing the huntingtin protein containing increasing CAG repeats secreted less apoE-lipoprotein-bound cholesterol in the medium. Conditioned media from HD astrocytes and lipoprotein-depleted conditioned media from wild-type (wt) astrocytes were equally detrimental in a neurite outgrowth assay and did not support synaptic activity in HD neurons, compared with conditions of cholesterol supplementation or conditioned media from wt astrocytes. Molecular perturbation of cholesterol biosynthesis and efflux in astrocytes caused similarly altered astrocyte-neuron cross talk, whereas enhancement of glial SREBP2 and ABCA1 function reversed the aspects of neuronal dysfunction in HD. These findings indicate that astrocyte-mediated cholesterol homeostasis could be a potential therapeutic target to ameliorate neuronal dysfunction in HD.